SGLT2 inhibitors in the treatment of diabetes Diyabet tedavisinde SGLT2 İnhibitörleri

Ceylan Ünlüsoy M., AkuÇ S., Inceli H. İ.

Fabad Journal of Pharmaceutical Sciences, cilt.43, sa.2, ss.67-80, 2018 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 43 Sayı: 2
  • Basım Tarihi: 2018
  • Dergi Adı: Fabad Journal of Pharmaceutical Sciences
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.67-80
  • Anahtar Kelimeler: Diabetes mellitus, Gliflozine, Glucose, Hyperglycemia, Insulin, SGLT2
  • Ankara Üniversitesi Adresli: Evet

Özet

© 2018 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved.Sodium-glucose co-transporter-2 (SGLT2) has an important role in renal glucose reabsorption in kidneys. Inhibition of SGLT2 is a new strategy for the treatment of diabetes mellitus by increasing glucose and energy loss through the urine in an insulin-independent manner. SGLT2 inhibitors have recently become available and represent a novel class of drugs for treatment of type 2 diabetes. In this study, it can be found some information about glucose homeostasis, role of kidneys in glucose homeostasis, renal gluconeogenesis, renal glucose uptake, SGLT system, the chemical structures, efficacy, potential clinical utility, structure-activity relationships and risks/benefits of SGLT2 inhibitors in the management of diabetes mellitus.